| Patient/sex/age (years) | Positive temp art | PMR | CRP (mg/l) | ESR(mm/1st h) | BVAS.2 | Thoracic activity* | PET whole- body act† | Immunosuppressive treatment‡ | Aortic wall ⩾4 mm | Vascular stenoses | Arm claudication | Aortic aneurysm | |
| PET | MRI | ||||||||||||
| 1/F/67 | + | 45 (<5) | 54 (20) | 9 (7) | 4 | 5 (3) | 7 | GC, MTX (↑GC, MTX) | + | + | + | ||
| 2/F/67 | + | 100 | 48 | 13 | 5 | 3 | 8 | GC (GC, MTX) | + | ||||
| 3/F/59 | + | 44 (22) | 56 (50) | 11 (2) | 2 (0) | 1 (0) | 2 (0) | GC (GC, MTX) | |||||
| 4/F/73 | 8 (16) | 68 (73) | 11 (3) | 1 | 2 (2) | 1 | GC, MTX (↑GC, MTX) | + | |||||
| 5/F/64 | + | + | <5 (<5) | 44 (42) | 2 (1) | 3 (0) | 4 (4) | 7 (0) | GC, Cyc (GC, Cyc) | + | + | + | |
| 6/F/75 | + | <5 | 24 | 2 | 0 | 2 | 0 | GC, MTX (GC, MTX) | + | ||||
| 7/F/75 | + | 26 | 40 | 5 | 2 | 0 | 2 | GC (↑GC) | |||||
| 8/M/60 | + | + | 12 | 82 | 8 | 2 | 2 | 2 | GC (GC, MTX) | + | |||
| 9/M/73 | + | + | <5 (<5) | 22 (13) | 7 (1) | 0 (0) | 0 (0) | 1 (2) | GC, MTX (GC, MTX) | + | + | ||
| 10/F/66 | 16 | 90 | 9 | 0 | 1 | 3 | GC (↑GC) | ||||||
| 11/F/80 | + | 108 | 50 | 12 | 0 | 0 | 3 | GC (GC, Cyc) | |||||
| 12/F/70 | + | + | 13 | 60 | 8 | 1 | 1 | 3 | GC, MTX (GC, Cyc) | ||||
| 13/M/63 | + | 10 (<5) | 34 (20) | 9 (3) | 2 (0) | 5 (1) | 7 (0) | GC, Cyc (GC, MTX, E) | + | + | + | ||
| 14/F/76 | 16 (34) | 31 (48) | 5 (5) | 1 (2) | 5 (4) | 2 (5) | GC, Cyc (↑GC, Cyc) | + | |||||
| 15/F/73 | 31 | 17 | 7 | 0 | 2 | 0 | GC, MTX (GC, Cyc) | + | + | ||||
| 16/M/61 | <5 (<5) | 5 (9) | 1 (0) | 0 | 1 (1) | 1 | GC (GC) | ||||||
| 17/F/53 | <5 | 20 | 1 | 4 | 4 | 5 | GC, MTX (GC, MTX) | + | |||||
| 18/F/62 | + | <5 (<5) | 19 (12) | 1 (2) | 0 (0) | 1 (1) | 0 | GC, MTX (GC, MTX) | + | + | |||
| 19/M/69 | + | <5 (<5) | 14 (13) | 2 (0) | 0 (0) | 2 (3) | 3 (2) | GC, MTX (GC, Cyc) | + | + | |||
| 20/F/60 | <5 | 18 | 3 | 1 | 1 | 1 | GC, MTX (GC, Cyc) | + | + | ||||
| 21/F/59 | + | + | 98 | 61 | 6 | 1 | 1 | 1 | GC, MTX (GC, MTX, E) | ||||
| 22/F/78 | + | 23 | 24 | 7 | 0 | 9 | 0 | GC, Cyc (↑GC, Cyc) | + | ||||
| 23/F/62 | + | 20 | 60 | 8 | 0 | 1 | 0 | GC (GC, MTX) | |||||
| 24/F/57 | <5 (<5) | 24 (20) | 3 (0) | 0 (0) | 7 (7) | 3 (2) | GC, MTX (↑GC, Cyc) | + | + | + | |||
| 25/F/52 | <5 (<5) | 42 (15) | 7 (0) | 9 (0) | 7 | 12 (0) | GC, Cyc (↑GC, Cyc) | + | + | ||||
*Thoracic activity: range 0–12 (comprehensive score of inflammatory activity in four vascular territories of the thoracic aorta and the supra-aortic arteries as assessed by MRI and PET: 0, no inflammatory activity; 1, slight disease activity; 2, marked activity; 3, intensive activity). †PET whole body activity: range 0–18 (including the abdominal aorta and the lower extremity arteries); in parentheses—follow-up data at the time of repeated imaging. ‡Immunosuppressive treatment: in parentheses—change of treatment, ↑increased dose.
BVAS.2, Birmingham Vasculitis Activity Score; CRP, C-reactive protein (normal range: <5 mg/l); Cyc, cyclophosphamide; E, etanercept; ESR, erythrocyte sedimentation rate according to the Westergren method (mm at the end of the first hour); GC, glucocorticosteroids; MTX, methotrexate; PMR, polymyalgia rheumatica; positive temp art, positive biopsy of the temporal artery.